SYNGENE Stock Overview
A contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
New Pharma Partnerships And Operational Efficiencies Will Strengthen Future Prospects
My Notes
Capture your thoughts, links and company narrative
Syngene International Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹714.60 |
| 52 Week High | ₹960.60 |
| 52 Week Low | ₹607.65 |
| Beta | 0.57 |
| 1 Month Change | -14.13% |
| 3 Month Change | -17.80% |
| 1 Year Change | -4.48% |
| 3 Year Change | 34.83% |
| 5 Year Change | 134.99% |
| Change since IPO | 360.22% |
Recent News & Updates
Syngene International Limited's (NSE:SYNGENE) Popularity With Investors Is Under Threat From Overpricing
Feb 15
We Think Syngene International (NSE:SYNGENE) Can Stay On Top Of Its Debt
Jan 24Recent updates
Syngene International Limited's (NSE:SYNGENE) Popularity With Investors Is Under Threat From Overpricing
Feb 15We Think Syngene International (NSE:SYNGENE) Can Stay On Top Of Its Debt
Jan 24Why Syngene International's (NSE:SYNGENE) Shaky Earnings Are Just The Beginning Of Its Problems
Oct 31Syngene International Limited's (NSE:SYNGENE) Popularity With Investors Is Under Threat From Overpricing
Jul 16These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely
Mar 28Do Syngene International's (NSE:SYNGENE) Earnings Warrant Your Attention?
Feb 14Earnings Not Telling The Story For Syngene International Limited (NSE:SYNGENE)
Jan 19Is Syngene International (NSE:SYNGENE) A Risky Investment?
Nov 19Is Now The Time To Put Syngene International (NSE:SYNGENE) On Your Watchlist?
Nov 01Syngene International (NSE:SYNGENE) Seems To Use Debt Rather Sparingly
Aug 07These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely
Apr 28Here's Why We Think Syngene International (NSE:SYNGENE) Is Well Worth Watching
Apr 06Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?
Jan 04Syngene International (NSE:SYNGENE) Has A Pretty Healthy Balance Sheet
Dec 08Is Syngene International (NSE:SYNGENE) Using Too Much Debt?
Aug 28Syngene International Limited (NSE:SYNGENE) Shares Could Be 22% Above Their Intrinsic Value Estimate
Aug 10Shareholder Returns
| SYNGENE | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | 1.8% | -3.4% | -2.5% |
| 1Y | -4.5% | 38.9% | -1.9% |
Return vs Industry: SYNGENE underperformed the Indian Life Sciences industry which returned 38.9% over the past year.
Return vs Market: SYNGENE underperformed the Indian Market which returned -1.9% over the past year.
Price Volatility
| SYNGENE volatility | |
|---|---|
| SYNGENE Average Weekly Movement | 4.1% |
| Life Sciences Industry Average Movement | 6.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: SYNGENE has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: SYNGENE's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 6,510 | n/a | www.syngeneintl.com |
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing and sterile fill-finish services. It also provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services.
Syngene International Limited Fundamentals Summary
| SYNGENE fundamental statistics | |
|---|---|
| Market cap | ₹282.64b |
| Earnings (TTM) | ₹5.02b |
| Revenue (TTM) | ₹35.41b |
57.2x
P/E Ratio8.1x
P/S RatioIs SYNGENE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYNGENE income statement (TTM) | |
|---|---|
| Revenue | ₹35.41b |
| Cost of Revenue | ₹11.19b |
| Gross Profit | ₹24.23b |
| Other Expenses | ₹19.21b |
| Earnings | ₹5.02b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 12.50 |
| Gross Margin | 68.41% |
| Net Profit Margin | 14.16% |
| Debt/Equity Ratio | 14.5% |
How did SYNGENE perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield10%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/20 17:23 |
| End of Day Share Price | 2025/02/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Syngene International Limited is covered by 19 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Asian Markets Securities Private Limited |
| Vijayaraghavan Swaminathan | Avendus Spark |
| Harith Ahamed | Avendus Spark |